COMP <GO>
VCYT vs ACHC // RSI-14 & 200D SMA MOMENTUM
Veracyte Inc. (NASDAQ) VS. Acadia Healthcare Company Inc. (NASDAQ) • 15-METRIC TALLY: VCYT 10
— ACHC 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: VCYT
LAST: $49.00 (-2.02%) • MKT CAP: $4.02B
rsi-technicals
57.7
LAST: $29.62 (-1.13%) • MKT CAP: $2.79B
rsi-technicals
50.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCYT VS. ACHC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCYT | ACHC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | -24.80% | +29.40 | VCYT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 58.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.02% | -16.04% | +19.06 | VCYT | /fcf-yield <GO> |
| Operating Margin | 11.20% | -40.60% | +51.80 | VCYT | /operating-margins <GO> |
| Net Profit Margin | 12.80% | -33.30% | +46.10 | VCYT | /net-margins <GO> |
| Revenue Growth (YoY) | 16.00% | 5.00% | +11.00 | VCYT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | VCYT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 57.7 | 50.9 | +6.80 | VCYT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.07 | +0.01 | VCYT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 53.1x | 21.0x | +32.10 | ACHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $2.79B | $1.23B | VCYT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCYT REV | ACHC REV | VCYT GROSS % | ACHC GROSS % | VCYT FCF | ACHC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $517.1M | $3.31B | 70.1% | — | $126.6M | -$439.9M |
| FY 2024 | $445.8M | $3.15B | 66.9% | — | $63.8M | -$560.7M |
| FY 2023 | $361.1M | $2.93B | — | — | $28.0M | $330.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCYT // BETA 1.08
ACHC // BETA 1.07